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Background: Cyclic phosphatidic acid (cPA) is a naturally occurring phospholipid mediator with a unique cyclic
phosphate ring at the sn-2 and sn-3 positions of its glycerol backbone. Natural cPA and its chemically stabilized cPA
derivative, 2-carba-cPA (2ccPA), inhibit chronic and acute inflammation, and 2ccPA attenuates neuropathic pain.
Osteoarthritis (OA) is a degenerative disease frequently associated with symptoms such as inflammation and joint
pain. Because 2ccPA has obvious antinociceptive activity, we hypothesized that 2ccPA might relieve the pain caused
by OA. We aimed to characterize the effects of 2ccPA on the pathogenesis of OA induced by total meniscectomy
in the rabbit knee joint.
Results: Intra-articular injection of 2ccPA (twice a week for 42 days) significantly reduced pain and articular swelling.
Histopathology showed that 2ccPA suppressed cartilage degeneration in OA. We also examined the effects of
2ccPA on the inflammatory and catabolic responses of human OA synoviocytes and chondrosarcoma SW1353
cells in vitro. 2ccPA stimulated synthesis of hyaluronic acid and suppressed production of the metalloproteinases
MMP-1, −3, and −13. However, it had no effect on the production of interleukin (IL)-6, an inflammatory cytokine.
The suppressive effect of 2ccPA on MMP-1 and −3 production in synoviocytes and on MMP-13 production in
SW1353 cells was not mediated by the lysophosphatidic acid receptor, LPA1 receptor (LPA1R).
Conclusions: Our results suggest that 2ccPA significantly reduces the pain response to OA by inducing hyaluronic
acid production and suppressing MMP-1, −3, and −13 production in synoviocytes and chondrocytes.
Keywords: Cyclic phosphatidic acid, 2-carba-cyclic phosphatidic acid, Osteoarthritis, Total meniscectomy,
Synoviocytes, Chondrocytes, Chonrosarcoma SW1353 cells, Hyaluronic acid, MetalloproteinaseBackground
Cyclic phosphatidic acid (cPA) is a naturally occurring
phospholipid mediator that was originally isolated from
the myxoamoebae of a true slime mold, Physarum polyce-
phalum, in 1992 [1]. Later, cPA was found in mammalian
tissues [2,3]. cPA has distinct biological activities; it in-
hibits autotaxin [4-6], suppresses cancer cell invasion and
metastasis [4,7], attenuates ischemia-induced delayed
neuronal cell death in rat hippocampal CA1 regions [8,9],
and inhibits chronic and acute inflammation-induced
C-fiber stimulation, and attenuates neuropathic pain [10].* Correspondence: murofushi.kimiko@ocha.ac.jp
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unless otherwise stated.Therefore, cPA is a promising candidate of therapeutic
agent for pain.
To develop this idea, we synthesized several chemically
stabilized derivatives of cPA. cPA has a unique structure
comprising of a cyclic phosphate ring at the sn-2 and
the sn-3 positions of the glycerol backbone (Figure 1A),
which is required for the biological activities of cPA [11].
In 2-carba-cPA (2ccPA), one of the phosphate oxygens is
replaced with a methylene group at the sn-2 position
(Figure 1B) [4,12]. In vivo, tritium labeled 2ccPA ([3H]
2ccPA) was intravenously injected to rats (30 mg/kg).
Then, it has been revealed the half-life of the tritium
labeled compound(s) was 81.7 h (unpublished data ob-
tained by Mitsubishi Chemical Medience Corporation).
In vitro, we have previously shown that cPA 18:1 is
stable in neutral-buffered aqueous medium for up to
24 h using liquid chromatography-mass spectroscopyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Structure of cPA and 2ccPA. (A) Structure of natural occurring cPA 18:1, and (B) chemically synthesized its derivative, 2ccPA 18:1,
used for the present experiments.
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over this time frame was not accompanied by a signifi-
cant increase in LPA levels [4], suggesting that cPA may
not be converted into LPA. Furthermore, we investigated
the stability of 2ccPA 18:1 in 1 mM phosphate buffered
saline using LC-MS/MS, and we revealed that 2ccPA
18:1 was stable for more than 2 weeks at 37°C and it
was not converted into LPA (unpublished data). We pre-
viously showed that 2ccPA retains many of the biological
functions of cPA and that it is a much more potent
inhibitor of cancer cell invasion and metastasis and a
stronger suppressor of the nociceptive reflex than na-
tural cPA [4,7,10,12].
Osteoarthritis (OA) is a degenerative disease frequently
associated with inflammation, joint pain, swelling, and
stiffness, leading to significant functional impairment and
disability at articular joints [13]. OA is caused by charac-
teristic structural alterations of the joint, including focal
degradation of articular cartilage, subchondral bone alte-
rations, and synovitis [14-16]. OA joints are the biological
site of inflammation and catabolism. Synovial inflam-
mation likely contributes to the dysregulation of cartilage
homeostasis, favoring an imbalance between the catabolic
and anabolic activities of chondrocytes in remodeling the
cartilage extracellular matrix (ECM) [17-19].
2ccPA inhibites chronic and acute inflammation-
induced C-fiber stimulation and attenuates neuropathic
pain [10]; we then assessed the ability of 2ccPA to relieve
OA-related pain in a rabbit model in vivo. In addition,
to investigate the molecular mechanisms of 2ccPA in
OA-related cells, we examined the effects of 2ccPA on
the inflammatory and catabolic responses of human OA
synoviocytes and chondrosarcoma SW1353 cells in vitro.
Results and discussion
Pain assessment
Figure 2B shows the change in right hind paw weight dis-
tribution (%) from Day 0 (surgery) to Day 42 (sacrifice) for
the vehicle- and 2ccPA-treated groups. From Days 7 to
14, both the vehicle- and 2ccPA-treated groups recovered
from the surgical stress observed between Days 0 and 7.
After Day 14, the weight distribution (%) of the right hind
paw of the vehicle-treated group gradually decreased withtime, indicating that OA symptoms were induced by men-
iscectomy. In the 2ccPA-treated group beginning on Day
21, the weight distribution (%) was higher than in the
vehicle-treated group. On Day 42, the weight distribution
(%) of the 2ccPA-treated group was 1.7-fold higher than
that of the vehicle-treated group. These results suggest
2ccPA reduces OA pain in the rabbit meniscectomy
model.
Inflammatory swelling assessment
Figure 2C shows the swelling ratio on Day 42 for the
vehicle- and 2ccPA-treated groups. The swelling ratio was
11.87 ± 3.54% in the vehicle-treated group and 0.45 ±
1.78% in the 2ccPA-treated group. These results suggest
2ccPA exerts a constraining influence on the swelling
resulting from OA inflammation in the rabbit meniscec-
tomy model. Therefore, we believe 2ccPA is effective for
relieving pain and reducing inflammation caused by OA.
Histopathology
We observed remarkable attenuation of pain and articu-
lar swelling in 2ccPA-treated animals 6 weeks after sur-
gery (Figure 2B and C). Therefore, we chose Day 42 to
evaluate the effects of 2ccPA on OA.
Figure 3 shows a representative section of hematoxylin
and eosin (HE)- and Safranine-O (Saf-O)-stained sections
of cartilage from the right medial condyle of the femur
and tibia in the vehicle- and 2ccPA-treated groups on Day
42. Stained-sections revealed typical changes of OA such
as disorcanization of chondrocytes (black circles), ex-
posure of subchondral bone (black arrowheads), cluster
formation (blue arrowheads), loss of chondrocytes (green
arrowheads), loss of the superficial layer (yellow arrow-
heads), and fissure (red arrowhead).
HE-staining revealed that chondrocyte disorganization
in the medial condyle of the femur was significant in
the vehicle-treated group. However, chondrocytes were
much more ordered in the 2ccPA-treated group than in
the vehicle-treated group. Cluster formation was also at-
tenuated in the 2ccPA-treated versus the vehicle-treated
group. Saf-O staining showed a significant loss of stain-
able proteoglycan in the vehicle-treated group. However,

































Figure 2 Effect of 2ccPA on hind-paw weight distribution and articular swelling in a rabbit model of OA. (A) Experimental schedule. OA
was induced by total meniscectomy in rabbits. Vehicle or 2ccPA was intra-articularly injected starting 7 days after surgery. (B) The change in
weight distribution (%) of the right hind paw from Day 0 to Day 42 in vehicle- (open-circles) and 2ccPA-(closed circles) treated groups. All data
are expressed as means ± standard error (SE). (C) The percent swelling score was also calculated and expressed as means ± SE. (*P < 0.05 and
**P < 0.01 vs. vehicle-treated controls).
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chondropathy and cartilage degeneration; in addition,
the loss of stainable proteoglycan, chondrocyte disorga-
nization, and cluster formation were considerably lower
in the 2ccPA-treated group.
Like the medial condyle of the femur, chondrocyte
disorganization and cluster formation in the medial con-
dyle of the tibia were significant in the vehicle-treated
group; however, these morphologic changes were reduced
in the 2ccPA-treated group. Saf-O staining showed that
the loss of stainable proteoglycan in the vehicle-treated
group was attenuated by 2ccPA.
Other morphologic changes in the medial condyle of
the femur and tibia, including loss of the superficial layer,
cartilage erosion, and fibrillation and/or fissures were
less substantial in the 2ccPA-treated group than in the
vehicle-treated group. Due to mechanical friction during
meniscectomy in the rabbit OA model, serious cartilage
degeneration occurs within a week after surgery and pro-
gresses gradually [20,21]. In this study, cartilage de-
gradation induced by meniscectomy was suppressed in
the 2ccPA-treated group, suggesting that in the rabbit OA
model, 2ccPA may influence pain and catabolic regulation;therefore, 2ccPA provided chondroprotective effects du-
ring OA progression.
Measurement of hyaluronic acid in synoviocyte and
chondrosarcoma SW1353 cells in vitro
Synovial inflammation likely contributes to dysregulation
of cartilage homeostasis, favoring an imbalance between
the catabolic and anabolic activities of the chondrocyte in
remodeling cartilage extra cellular matrix (ECM). Cartilage
tissue is altered and damaged by inflammatory mediators
and degradative enzymes in the synovial fluid of OA
[17-19] and the proportion of high-molecular-weight hya-
luronic acid decrease while the inflammatory cytokines
and ECM-degrading enzyme MMPs increase [17,19,20,22].
The pain and swelling scores in this study demonstrated
the antinociceptive and anti-inflammatory effects of 2ccPA
administration. Therefore, we investigated the chondro-
protective effects of 2ccPA in vitro by using synoviocytes
and chondrosarcoma cell line SW1353, an in vitro model
for primary chondrocytes in OA.
We initially studied the effects of 2ccPA on the pro-
duction of hyaluronic acid by enzyme-linked immuno-
sorbent assay, ELISA. As shown in Figure 4, the amount
Figure 3 (See legend on next page.)
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Figure 3 Histopathology of the medial condyle of the femur and tibia with or without 2ccPA treatment. Hematoxylin and eosin (HE)- and
Safranine (Saf)-O–stained sections of the cartilage of the right medial condyle of the femur and tibia on Day 42 after surgery. Original magnification × 10
(A), ×200 (B), and × 600 (C1 and C2). Disorganization of chondrocytes (black circles), exposure of subchondral bone (black arrowheads), cluster
formation (blue arrowheads), loss of chondrocytes (green arrowheads), loss of the superficial layer (yellow arrowheads), and fissure (red arrowhead)
are shown.
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both cell types and 2ccPA significantly increased hya-
luronic acid secretion in a dose-dependent manner in
synoviocytes (Figure 4A). Compared with vehicle, 10 μM
2ccPA enhanced hyaluronic acid secretion by 3.2-fold in
synoviocytes. On the other hand, SW1353 cells increased
production of hyaluronic acid over time, but were un-
affected by 2ccPA (Figure 4B). Hyaluronic acid synthetic
capacity is much lower in SW1353 cells than in synovio-
cytes; therefore 2ccPA might not stimulate hyaluronic
acid synthesis in SW1353 cells. We suggest 2ccPA
stimulates synoviocytes to synthesize hyaluronic acid,
thus providing an apparent chondroprotective effect.
High-molecular-weight hyaluronic acid inhibits IL-1β-
stimulated production of MMP-1, −3, and −13 in chon-
drocytes [21,23-25]. Therefore, hyaluronic acid induced
by 2ccPA may inhibit the production of inflammatory
cytokines and MMP-1, −3, and −13 in synoviocytes and
SW1353 cells. We investigated the effects of 2ccPA on
the inflammatory cytokines and MMPs production of
both cells.
Inflammatory cytokine expression and secretion from
IL-1β-stimulated synoviocytes and chondrosarcoma
SW1353 cells
By using quantitative real-time PCR, we investigated
transcript expression of inflammatory cytokines IL-1β,Figure 4 Effect of 2ccPA on production of hyaluronic acid by synovio
cultured with 1, 3, or 10 μM 2ccPA for the time indicated. The concentratio
Data represent the mean ± SE of triplicate independent experiments (*P <IL-6, IL-8, and TNF-α in synoviocytes and SW1353 cells.
As shown in Figure 5A, IL-1β treatment for 24 h in-
creased transcript expression of IL-6 and −8, but not
TNF-α and IL-1β (data not shown) in synoviocytes.
Primary rheumatoid synovial fibroblasts stimulated by
IL-1β exhibit increased IL-6 and IL-8 secretion, but
TNF-α is not affected [26]. Although the synoviocytes
used in this study were obtained from OA patients, the
induction of inflammatory cytokines upon stimulation
with IL-1β was similar to that of rheumatoid synovial fi-
broblasts. IL-1β treatment of SW1353 cells induced
transcript expression of IL-6, −8, and TNF-α with a
maximum at 3 h (data not shown) that was maintained
for 24 h (Figure 5B). Expression of IL-1β mRNA did not
change over the 24 h assay period (data not shown). The
induction of inflammatory cytokines by IL-1β was
slightly affected by 2ccPA, and these results suggest that
2ccPA did not have a dramatic effect on inflammatory
cytokine production.
It has been reported that the production of inflammatory
cytokine IL-6 increases in OA joints and triggers catabolic
reactions [16,17]. Then, we performed ELISA to measure
the production of IL-6 by both cells in culture media. The
amount of IL-6 produced by IL-1β–stimulated synovio-
cytes and SW1353 cells increased to 12.9 ± 0.2 ng/mL and
0.254 ± 0.011 ng/mL, respectively (Figure 5). On synovio-
cytes, NSAIDs treatment reduced the inductive effect whilecytes and SW1353 cells. Synoviocytes (A) and SW1353 cells (B) were
ns of hyaluronic acid in culture media were determined with ELISA.
0.05 and **P < 0.01 vs. vehicle-treated controls).
Figure 5 Effect of 2ccPA on mRNA expression and production of inflammatory cytokines. To measure mRNA expression, synoviocytes
(A) and SW1353 cells (B) were cultured with 1 or 10 μM 2ccPA for 24 h in the presence or absence of 10 ng/mL IL-1β. mRNA levels of each gene
were determined by quantitative real-time PCR. Data represent the mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs.
vehicle-treated controls). To measure IL-6 concentrations in the culture media of synoviocytes (A) and SW1353 cells (B), cells were cultured with
10 μM 2ccPA, IBF or DCF in the presence of 10 ng/mL IL-1β. After 24 h incubation, culture media were collected, and IL-6 concentrations were
determined by ELISA. Data represent the mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs. vehicle-treated controls).
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On the other hand, NSAIDs and 2ccPA showed negligible
effects on IL-6 production in SW1353 cells (Figure 5B).
MMP-1, −3, and −13 expression and secretion from
IL-1β-stimulated synoviocytes and chondrosarcoma
SW1353 cells
To investigate the effects of 2ccPA on production of
ECM-degrading enzymes by synoviocytes and SW1353
cells, we measured MMP-1, −3, and −13, which increase
in OA joints and play a role in OA progression [16,18,19].
Transcript expression of MMP-1, −3, and −13 in IL-1β-
stimulated synoviocytes and SW1353 cells was assessed by
quantitative real-time PCR. IL-1β induced expression of
MMP-1, −3, and −13 in both synoviocytes and SW1353
cells after 24 h treatment as shown in Figure 6. The in-
duction of MMPs in synoviocytes and SW1353 cells were
significantly reduced by 1, and 10 μM 2ccPA (Figure 6).
To investigate the effect of 2ccPA on IL-1β-stimulated
MMP-1, −3, and −13 protein expression in synoviocytes
and SW1353 cells, we assessed the levels of MMPs se-
creted into the culture medium.
MMP-1 production increased to 4.9 ± 0.2 ng/mL and
0.60 ± 0.06 ng/mL with IL-1β stimulation in synovio-
cytes and SW1353 cells, respectively. In synoviocytes,
MMP-1 secretion was suppressed dose-dependently by
3 and 10 μM 2ccPA. In SW1353 cells, MMP-1 secretion
was suppressed by 1 and 3 μM 2ccPA but dose-dependency was poor. These results suggest that to
elicit suppressive function of 2ccPA, it is necessary to
choose a certain dose depending on cell types.
MMP-3 production increased to 68.7 ± 4.8 ng/mL
and 20.3 ± 1.3 ng/mL with IL-1β stimulation in syno-
viocytes and SW1353 cells, respectively. MMP-3 pro-
duction was much higher than that of MMP-1 and −13.
In synoviocytes, MMP-3 secretion was suppressed
dose-dependently by 2ccPA. In contrast, MMP-3 secre-
tion in SW1353 cells was not affected by 2ccPA
treatment.
MMP-13 production increased to 0.81 ± 0.18 ng/mL
with IL-1β stimulation in SW1353 cells, and the MMP-13
secretion was suppressed by 2ccPA. Although expres-
sion of MMP-13 mRNA was observed in synoviocytes
(Figure 6A), the amount of protein was not detected.
There are some reports that MMP-1 and −13 degrade
collagen and are expressed in synoviocytes and chon-
drocytes, respectively [18,19]. MMP-3 degrades non-
collagen matrix components of the joint and contributes
to proteoglycan loss [18,19]; its expression is high in
comparison to other MMPs [18]. Our results are con-
sistent with these reports. We suggest that the obvious
suppressive effects of 2ccPA on MMP-1 and −3 produc-
tion in synoviocytes, and on MMP-13 in chondrosar-
coma SW1353 cells may offer the appropriate evidence
to explain the chondroprotective effect we observed
in vivo (Figure 3).
Figure 6 Effect of 2ccPA on mRNA expression and production of MMP-1, −3, and −13. To measure mRNA expression, synoviocytes (A) and
SW1353 cells (B) were cultured with 1 or 10 μM 2ccPA for 24 h in the presence or absence of 10 ng/mL IL-1β. mRNA levels were determined by
quantitative real-time PCR. Data represent the mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs. vehicle-treated
controls). To measure MMPs in the culture media of synoviocytes (A) and SW1353 cells (B), cells were cultured with 1, 3, or 10 μM 2ccPA in the
presence of 10 ng/mL IL-1β. After 24 h incubation, culture media were collected and the concentration of each MMP was measured by ELISA.
Data represent the mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs. vehicle-treated controls). N.D. stands for
not detected.
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2ccPA in OA
The pathophysiology of OA appears to be mediated by
imbalances between the anabolic and catabolic activity
of articular chondrocytes and other joint tissue cells such
as synoviocytes [14-19]. Inhibition of the LPA1R has been
reported to have therapeutic benefits in Japanese OA [27],
although these results were not replicated in a larger
sample [28]. Although 2ccPA is an agonist of LPA1R
[4], it suppressed OA pathogenesis in vivo. We investi-
gated the association of these properties of 2ccPA with
the LPA1R signaling pathway and found that synovio-
cytes and SW1353 cells expressed high levels of LPA1R
(Figure 7). In order to examine the involvement of
LPA1R in IL-1β-stimulated MMPs production, we
tested Ki16425, a selective antagonist for LPA1R and
LPA3R. In synoviocytes, Ki16425 did not influence onMMP-1 and −3 production, and it showed no influence
on the suppressive effects of 2ccPA on MMP-1 and −3
production (Figure 8A). These results suggest the major
receptor for 2ccPA suppression of MMPs in synovio-
cytes may not be LPA1R. On the other hand, in SW1353
cells, Ki16425 attenuated MMP-1 inhibition by 1 and
3 μM 2ccPA (Figure 8B), but had no effect on MMP-13
production (Figure 8B). Thus, we suggest the major re-
ceptor for MMP-13 suppression by 2ccPA in SW1353
cells may not be LPA1R, although this receptor may be
involved in MMP-1 suppression. We need to identify
the receptor involved in 2ccPA-mediated suppression of
MMP-1, −3, and −13 expression hereafter.
Previous studies have suggested that hyaluronic acid
reduces MMPs expression in synovial fluid [21,23-25].
Therefore, MMP-1, −3, and −13 suppression by 2ccPA
might be due to a 2ccPA-mediated increase in
Figure 7 Expression of LPA receptors in human synoviocytes and SW1353 cells. Total RNA was extracted and expression of each LPA
receptor in synoviocytes (A) and SW1353 cells (B) was determined by quantitative real-time PCR.
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to clarify how 2ccPA modulates MMPs expression.
OA causes morbidity, activity limitation, physical dis-
ability, excess health care utilization, and reduces health-
related quality of life (QOL), especially in people over
60 years old. However, OA management is now limited
to the symptomatic treatment of pain and inflammation
without reducing joint destruction, which leads to in-
evitable referral for total joint replacement. Given this
unresolved therapeutic need, many challenges remain in
the discovery and development of disease-modifying OA
drugs (DMOADs) aimed at slowing, halting, or reversing
the progression of structural damage of the articular car-
tilage [29,30]. We believe 2ccPA is a promising DMOAD
candidate. The pain-relieving mechanisms of 2ccPA in
the pathogenesis of OA are now under investigation.Conclusions
Our results suggest 2ccPA significantly reduces the pain
response to OA by inducing hyaluronic acid production
and suppressing MMP-1, −3, and −13 production in syno-
viocytes and chondrocytes. These activities might protect
chondrocytes from destruction. As a result, pain and in-
flammatory swelling are relieved. It is strongly suggested
that 2ccPA is a promising candidate of DMOAD.Materials and methods
Drug
We used chemically synthesized 2-carba-cPA 18:1 (2ccPA)
[4,7]. In the in vivo experiments, 2ccPA was dissolved in
saline, and saline was used as vehicle. In the in vitroexperiments, 2ccPA was dissolved in phosphate-buffered
saline (PBS) containing 0.1% fatty acid-free bovine serum
albumin (BSA), and PBS containing 0.1% BSA solution
was used as vehicle.OA model
A rabbit model was used to investigate the effects of
2ccPA on the pathogenesis of OA. The design of this
animal study was approved by the ethics committee of
KAC Corporation (Ethics approval number: 12–0218), a
contract research organization (Shiga Japan). All animals
were purchased from KITAYAMA LABES Co., Ltd.
(Japan), and all animal experiments were performed
by KAC Corporation using 11- or 12-week-old male
SPF New Zealand white rabbits (n = 12, body weight
2.1–2.3 kg). Animals were anesthetized with intravenous
(i.v.) pentobarbital (32.4 mg/kg) prior to 1–4% isoflurane
followed by subcutaneous infusion of lidocaine (approx.
3 mL) during surgery.
The meniscus of the right leg was totally removed.
Briefly, the boundary between the patellar ligament and
articular capsule of the right hind leg and the lateral-
collateral ligament were dissected. Then, the articular
capsule was removed to expose the interior meniscus, and
the meniscus was completely removed. Following total
meniscectomy of the right knee joint, the rabbits were
randomly divided into vehicle- or 2ccPA-treated group.
Intra-articular treatment was initiated 7 days after surgery.
Vehicle (200 μL saline; Otsuka Pharmaceutical Co., Ltd.,
Tokyo, Japan) or 50 μg/mL 2ccPA (200 μL) was injected
into the joint cavity twice per week over five consecutive
Figure 8 Effect of Ki16425 on the suppressive function of 2ccPA on MMP-1, −3, and −13 production in synoviocytes and SW1353 cells.
Synoviocytes (A) or SW1353 cells (B) were pre-incubated with 10 μM Ki16425 for 30 min, then treated with 1, 3, or 10 μM 2ccPA for 24 h in the
presence of 10 ng/mL IL-1β. The culture media were collected and the concentration of each MMP was measured by ELISA. Data represent the
mean ± SE of triplicate independent experiments (*P < 0.05 and **P < 0.01 vs. vehicle-treated controls).
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surgery). The animals were individually caged (48.5 × 30 ×
35 cm3), received tap water ad libitum, and were fed a
standard diet (CR-3, 150 g/day; CLEA, Japan Inc.)
throughout the trials. During the experiments, the SPF
room temperature was 18°C with unidirectional airflow
systems; lighting was provided for 12 h daily (7:00 AM–
19:00 PM). The experimental schedule is shown in
Figure 2A.
Measurement of pain
Changes in hind paw weight distribution between the
right (OA model) and left (contralateral control)
limbs were measured as a pain index [21]. Hind-paw
weight distribution was measured once a week (at 7,
14, 21, 28, 32, and 35 days after surgery). Thepercentage of weight distribution of the right hind
paw was calculated with the following equation:
Weight distribution of right hind paw %ð Þ ¼ ðweight of the right leg=
kg½  weight right þ left leg kg½ Þ  100
Measurement of swelling
At 42 days after meniscectomy, articular swelling
was measured with a digital vernier caliper. The
maximum widths of the right and left hind paw were
measured and recorded. The percentage of swelling
was calculated as follows:
Swelling ratio %ð Þ ¼ ½ width of the right kneemm−width of the left knee mm½ ð Þ=
width of the right knee mm½  þ width of the left knee mm½ ð Þ  100
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At 42 days after meniscectomy, the rabbits were eutha-
nized by exsanguination immediately after pentobarbital
(32.4 mg/kg) administration. The femoral condyle and
tibial plateau were resected and immediately fixed in
10% formalin buffer. After decalcification with ethylene-
diaminetetraacetic acid (EDTA), the samples were cut
into 4-μm sections, then stained with HE for general
morphology, or Saf-O for proteoglycan, and were ob-
served using a 2.0 MP microscope (H-Micron, Hyogo,
Japan, Figure 3A) and an optical microscope BX51TF
(OLYMPUS, Tokyo, Japan, Figure 3B, 3C1 and 3C2). Im-
ages of 3–6 microscopic fields were incorporated into
one image for Figure 3A.
Cell culture and measurement of hyaluronic acid, IL-6,
and MMP-1, −3, and −13 produced by synoviocytes and
chondrosarcoma SW1353 cells
All procedures were specifically approved by the ethics
committee of Ochanomizu University (Ethics approval
number: 24–12) and the National Institute of Biomedical
Innovation, Japanese Collection of Research Bioresources
Cell Bank (previously Health Science Research Resources
Bank, Ethics approval number: 36); the patient gave full
written informed consent for tissue donation. Synovial
tissue was excised from the knee joint of a 60-year-old
female patient with OA during replacement surgery.
The patient-derived synoviocytes (Japanese Collection of
Research Bioresources Cell Bank, HT91989516, Lot.
07042011) were plated at 1.5 × 104 cells/well with
Dulbecco’s modified Eagle medium (DMEM) contai-
ning 10% fetal bovine serum (FBS, Life Technologies
Corporation, CB) on 12-well plates and incubated over-
night at 37°C in humidified 95% air and 5% CO2 atmos-
phere. Chondrosarcoma SW1353 cells were obtained from
American Type Culture Collection (ATCC) (no. HTB-94)
and were plated at 1.5 × 104 cells/well with DMEM con-
taining 10% FBS on 12-well plates and incubated overnight
as well as synoviocytes. The medium was replaced with
serum-free DMEM, and the cells were serum-starved for
16 h. To measure hyaluronic acid, 2ccPA was added after
serum starvation at final concentrations of 1, 3, and 10 μM
and incubated. The culture media were collected at 24, 48,
and 72 h, then the concentration of hyaluronic acid was
measured by ELISA (R&D Systems, Inc. MN).
To measure IL-6 and MMPs, the cells were treated with
either 10 μM of ibuprofen (IBF), diclofenac sodium (DCF)
(Wako Pure Chemical Industries, Ltd. Osaka, Japan), or
various concentrations of 2ccPA for 24 h in the presence
of 10 ng/mL of IL-1β (R&D Systems, Inc.). Culture media
were collected at 24 h and the concentrations of IL-6 and
MMPs were measured by ELISA kit according to the
manufacturer’s instructions (RayBiotech, Inc., GA). For
treatment with Ki16425 (Cayman Chemicals, MI), theselective antagonist for LPA1R and LPA3R, the cells were
plated at 1.5 × 104 cells/well on 12-well plates and incu-
bated for 30 min with 10 μM of Ki16425 before adding
2ccPA (1, 3, or 10 μM) in the presence of 10 ng/mL IL-1β.
Culture media were collected at 24 h and the concentra-
tion of each MMP was measured by ELISA kit.
Quantitative real-time reverse transcription-polymerase
chain reaction (RT-PCR)
To quantitate the mRNA levels of inflammatory cytokines
(IL-1β, IL-6, IL-8, TNF-α), MMPs (MMP-1, −3, −13), and
LPA receptors, real-time RT-PCR was performed with
SYBR Premix Ex Taq (Takara Bio, Inc., Shiga, Japan). Total
RNA was extracted from cultured synoviocytes and
SW1353 cells using ISOGEN reagent (Nippon Gene,
Tokyo, Japan) according to the manufacturer’s instructions.
cDNA was synthesized with the PrimeScript RT reagent
kit (Takara Bio, Inc.). mRNA levels were quantified on a
lightCycler 96 system (Roche) instrument. Gene-specific
primer sets for IL-1β, IL-6, IL-8, MMP-3, and −13 were de-
scribed in [31]. Gene-specific primer sets for TNF-α and
MMP-1 were described in [32]. Gene-specific primer sets
for LPA1R, LPA4R, LPA5R, LPA6R, and p2y10 were
described in [7]. The following primer sets were used:
GAPDH, 5′-GTGAAGGTCGGAGTCAACG-3′ (F) and
5′-TGAGGTCAATGAAGGGGTC-3′ (R); LPA2R, 5′-GA
GGCCAACTCACTGGTCA-3′ (F) and 5′-GGCGCATC
TCAGCATCTC-3′ (R); LPA3R, 5′-GAAGCTAATGAA
GACGGTGATGA-3′ (F) and 5′-AGCAGGAACCACC
TTTTCAC-3′ (R); and GPR87, 5′-AAATCCAGCAGG
CAATTCAT-3′ (F) and 5′-CCCTGATGCTCTGGTTAT
GTT-3′ (R).
The data were calculated based on the Cq values, and
the expression of each gene was normalized to GAPDH.
Statistical analyses
All values are reported as means ± standard error. The
data were analyzed using the Student’s t-test. A P value
less than 0.05 was considered statistically significant.
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